HRP20161349T1 - 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]piramidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on - Google Patents
7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]piramidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on Download PDFInfo
- Publication number
- HRP20161349T1 HRP20161349T1 HRP20161349TT HRP20161349T HRP20161349T1 HR P20161349 T1 HRP20161349 T1 HR P20161349T1 HR P20161349T T HRP20161349T T HR P20161349TT HR P20161349 T HRP20161349 T HR P20161349T HR P20161349 T1 HRP20161349 T1 HR P20161349T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- methyl
- pharmaceutically acceptable
- diazaspiro
- Prior art date
Links
- GCZUIPVRHLYYOG-UHFFFAOYSA-N 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one Chemical compound O=C1N(C)CCC11NC(C=2N=C(C=C(C)N=2)C=2C=CC(=CC=2)C(F)(F)F)CC1 GCZUIPVRHLYYOG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002466 imines Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- -1 (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl] -1,7-diazaspiro[4.4]nonan-6-one hydrate salt Chemical compound 0.000 claims 1
- GCZUIPVRHLYYOG-BEFAXECRSA-N (2r,5s)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one Chemical class O=C1N(C)CC[C@]11N[C@@H](C=2N=C(C=C(C)N=2)C=2C=CC(=CC=2)C(F)(F)F)CC1 GCZUIPVRHLYYOG-BEFAXECRSA-N 0.000 claims 1
- PWYKAPTWUKNYOC-WSCVZUBPSA-N (2r,5s)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one;hydrochloride Chemical compound Cl.O=C1N(C)CC[C@]11N[C@@H](C=2N=C(C=C(C)N=2)C=2C=CC(=CC=2)C(F)(F)F)CC1 PWYKAPTWUKNYOC-WSCVZUBPSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (10)
1. Spoj formule (I) koji je 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on:
[image]
ili njegova farmaceutski prikladna sol.
2. Spoj prema zahtjevu 1 ili njegova farmaceutski prikladna sol, gdje spoj formule (I) jest spoj formule (Ia):
[image]
3. Spoj formule (I) prema zahtjevu 1 ili zahtjevu 2, koji je (2R,5S)-7-Metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on hidroklorid (E1).
4. Spoj formule (I) prema zahtjevu 1 ili zahtjevu 2, koji je (2R,5S)-7-Metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on sol sumporne kiseline (E2).
5. Spoj formule (I) prema zahtjevu 1 ili zahtjevu 2, koji je (2R,5S)-7-Metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on hidrat soli sumporne kiseline (E3).
6. Farmaceutski pripravak koji sadrži spoj formule (I) prema bilo kojem od zahtjeva 1 do 5 ili njegovu farmaceutski prikladnu sol s jednim ili više farmaceutski prikladnih nosača, punila i/ili pomoćnih tvari.
7. Spoj formule (I) prema bilo kojem od zahtjeva 1 do 5 ili njegova farmaceutski prikladna sol za uporabu u liječenju.
8. Spoj formule (I) prema bilo kojem od zahtjeva 1 do 5 ili njegova farmaceutski prikladna sol za uporabu u liječenju bolesti ili stanja posredovanih modulacijom natrijskih kanala reguliranih naponom.
9. Uporaba spoja formule (I) prema bilo kojem od zahtjeva 1 do 5 ili njegove farmaceutski prikladne soli u proizvodnji lijeka za liječenje bolesti ili stanja posredovanih modulacijom natrijskih kanala reguliranih naponom.
10. Postupak pripreme spoja formule (I) prema zahtjevu 1, koji obuhvaća:
(a) formiranje spoja formule (I) provođenjem reakcije zatvaranja prstena spoja formule (II) nakon čega slijedi redukcija dobivenog imina (IIA):
[image]
(b) uklanjanje zaštite sa zaštićenog derivata spoja formule (I);
(c) izborno formiranje farmaceutski prikladne soli spoja formule (I).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650325P | 2012-05-22 | 2012-05-22 | |
| GB201209015A GB201209015D0 (en) | 2012-05-22 | 2012-05-22 | Novel compounds |
| US201361773710P | 2013-03-06 | 2013-03-06 | |
| EP13725438.9A EP2861602B1 (en) | 2012-05-22 | 2013-05-22 | 7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one |
| PCT/GB2013/051335 WO2013175205A1 (en) | 2012-05-22 | 2013-05-22 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161349T1 true HRP20161349T1 (hr) | 2017-01-27 |
Family
ID=46546493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161349TT HRP20161349T1 (hr) | 2012-05-22 | 2016-10-17 | 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]piramidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on |
| HRP20200580TT HRP20200580T1 (hr) | 2012-05-22 | 2020-04-06 | Novi spojevi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200580TT HRP20200580T1 (hr) | 2012-05-22 | 2020-04-06 | Novi spojevi |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US9309254B2 (hr) |
| EP (3) | EP2861594B1 (hr) |
| JP (3) | JP6169687B2 (hr) |
| KR (2) | KR102161101B1 (hr) |
| CN (2) | CN104640867B (hr) |
| AU (3) | AU2013265001B2 (hr) |
| BR (1) | BR112014029280B1 (hr) |
| CA (1) | CA2873956C (hr) |
| CY (2) | CY1118274T1 (hr) |
| DK (2) | DK2861602T3 (hr) |
| EA (1) | EA025579B1 (hr) |
| ES (3) | ES2602308T3 (hr) |
| GB (1) | GB201209015D0 (hr) |
| HK (1) | HK1209423A1 (hr) |
| HR (2) | HRP20161349T1 (hr) |
| HU (2) | HUE031664T2 (hr) |
| IL (4) | IL235805A (hr) |
| IN (1) | IN2014MN02393A (hr) |
| LT (2) | LT2861602T (hr) |
| MX (1) | MX355303B (hr) |
| PL (2) | PL2861602T3 (hr) |
| PT (2) | PT3106464T (hr) |
| RS (2) | RS55415B1 (hr) |
| SG (2) | SG11201407755UA (hr) |
| SI (2) | SI2861602T1 (hr) |
| SM (1) | SMT201600421B (hr) |
| WO (2) | WO2013175206A1 (hr) |
| ZA (1) | ZA201408253B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| CN111343978A (zh) * | 2017-09-28 | 2020-06-26 | 生物基因公司 | 新型盐 |
| EP3694510A4 (en) | 2017-10-10 | 2021-06-30 | Biogen Inc. | SPIRO DERIVATIVE PREPARATION PROCESS |
| WO2022133097A1 (en) * | 2020-12-17 | 2022-06-23 | Biogen Ma Inc. | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05000370A (es) * | 2002-07-05 | 2005-04-19 | Targacept Inc | Compuestos n-aril diazaespiraciclicos y metodos de preparacion y usos de los mismos. |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| JP2009511599A (ja) * | 2005-10-12 | 2009-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 |
| WO2007084314A2 (en) * | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| US20110294842A9 (en) | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| US20110237567A9 (en) * | 2006-10-12 | 2011-09-29 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| EP2117538A1 (en) * | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| JP5855000B2 (ja) | 2009-09-14 | 2016-02-09 | クオンベルゲンセ プハルマセウトイカルス リミテッド | α−カルボキサミド誘導体の製造方法 |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| KR20140139000A (ko) * | 2012-03-21 | 2014-12-04 | 인터디지탈 패튼 홀딩스, 인크 | 무선 네트워크에서 다른 이동국에 의한 이동국 세션의 스폰서링 |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| GB201209670D0 (en) | 2012-05-31 | 2012-07-18 | Convergence Pharmaceuticals | Novel compounds |
-
2012
- 2012-05-22 GB GB201209015A patent/GB201209015D0/en not_active Ceased
-
2013
- 2013-05-22 SI SI201330339A patent/SI2861602T1/sl unknown
- 2013-05-22 EP EP13725439.7A patent/EP2861594B1/en not_active Not-in-force
- 2013-05-22 KR KR1020147035444A patent/KR102161101B1/ko active IP Right Grant
- 2013-05-22 PL PL13725438T patent/PL2861602T3/pl unknown
- 2013-05-22 EA EA201492169A patent/EA025579B1/ru unknown
- 2013-05-22 ES ES13725439.7T patent/ES2602308T3/es active Active
- 2013-05-22 ES ES16177700T patent/ES2782088T3/es active Active
- 2013-05-22 EP EP16177700.8A patent/EP3106464B1/en active Active
- 2013-05-22 HU HUE13725438A patent/HUE031664T2/en unknown
- 2013-05-22 IN IN2393MUN2014 patent/IN2014MN02393A/en unknown
- 2013-05-22 LT LTEP13725438.9T patent/LT2861602T/lt unknown
- 2013-05-22 US US14/403,480 patent/US9309254B2/en not_active Expired - Fee Related
- 2013-05-22 DK DK13725438.9T patent/DK2861602T3/en active
- 2013-05-22 WO PCT/GB2013/051336 patent/WO2013175206A1/en active Application Filing
- 2013-05-22 RS RS20160960A patent/RS55415B1/sr unknown
- 2013-05-22 EP EP13725438.9A patent/EP2861602B1/en active Active
- 2013-05-22 HU HUE16177700A patent/HUE049445T2/hu unknown
- 2013-05-22 BR BR112014029280-9A patent/BR112014029280B1/pt not_active IP Right Cessation
- 2013-05-22 WO PCT/GB2013/051335 patent/WO2013175205A1/en active Application Filing
- 2013-05-22 JP JP2015513266A patent/JP6169687B2/ja not_active Expired - Fee Related
- 2013-05-22 SG SG11201407755UA patent/SG11201407755UA/en unknown
- 2013-05-22 MX MX2014014274A patent/MX355303B/es active IP Right Grant
- 2013-05-22 US US14/403,473 patent/US9376445B2/en not_active Expired - Fee Related
- 2013-05-22 CN CN201380038180.6A patent/CN104640867B/zh not_active Expired - Fee Related
- 2013-05-22 PL PL16177700T patent/PL3106464T3/pl unknown
- 2013-05-22 RS RS20200393A patent/RS60368B1/sr unknown
- 2013-05-22 CA CA2873956A patent/CA2873956C/en active Active
- 2013-05-22 PT PT161777008T patent/PT3106464T/pt unknown
- 2013-05-22 SG SG10201703527WA patent/SG10201703527WA/en unknown
- 2013-05-22 CN CN201710522297.1A patent/CN107344942B/zh not_active Expired - Fee Related
- 2013-05-22 PT PT137254389T patent/PT2861602T/pt unknown
- 2013-05-22 LT LTEP16177700.8T patent/LT3106464T/lt unknown
- 2013-05-22 SI SI201331705T patent/SI3106464T1/sl unknown
- 2013-05-22 ES ES13725438.9T patent/ES2602193T3/es active Active
- 2013-05-22 KR KR1020207027461A patent/KR20200113027A/ko not_active Application Discontinuation
- 2013-05-22 JP JP2015513267A patent/JP2015517562A/ja not_active Withdrawn
- 2013-05-22 DK DK16177700.8T patent/DK3106464T3/da active
- 2013-05-22 AU AU2013265001A patent/AU2013265001B2/en not_active Ceased
-
2014
- 2014-11-11 ZA ZA2014/08253A patent/ZA201408253B/en unknown
- 2014-11-20 IL IL235805A patent/IL235805A/en active IP Right Grant
-
2015
- 2015-10-16 HK HK15110155.3A patent/HK1209423A1/xx not_active IP Right Cessation
-
2016
- 2016-02-15 US US15/043,920 patent/US20160184306A1/en not_active Abandoned
- 2016-05-25 US US15/163,845 patent/US9737536B2/en active Active
- 2016-10-17 HR HRP20161349TT patent/HRP20161349T1/hr unknown
- 2016-11-09 CY CY20161101143T patent/CY1118274T1/el unknown
- 2016-11-21 SM SM201600421T patent/SMT201600421B/it unknown
-
2017
- 2017-03-01 AU AU2017201421A patent/AU2017201421B2/en not_active Ceased
- 2017-04-30 IL IL252033A patent/IL252033B/en active IP Right Grant
- 2017-06-28 JP JP2017125716A patent/JP6378404B2/ja not_active Expired - Fee Related
- 2017-07-11 US US15/646,552 patent/US10010551B2/en active Active
-
2018
- 2018-03-07 AU AU2018201653A patent/AU2018201653B2/en not_active Ceased
- 2018-06-27 US US16/019,886 patent/US10485801B2/en not_active Expired - Fee Related
-
2019
- 2019-10-17 US US16/655,970 patent/US20200289508A1/en not_active Abandoned
- 2019-12-11 IL IL271330A patent/IL271330B/en active IP Right Grant
-
2020
- 2020-04-06 HR HRP20200580TT patent/HRP20200580T1/hr unknown
- 2020-04-07 CY CY20201100326T patent/CY1123044T1/el unknown
-
2021
- 2021-02-02 IL IL280595A patent/IL280595A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161349T1 (hr) | 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]piramidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| HRP20171197T1 (hr) | Bifenilsulfonamidni antagonist receptora endotelina i angiotensina ii, namijenjen liječenju glomeruloskleroze | |
| HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
| EA201490419A1 (ru) | Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания | |
| JP2013542247A5 (hr) | ||
| JP2012255026A5 (hr) | ||
| PH12014502041A1 (en) | Heterocyclyl compounds as mek inhibitors | |
| HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
| JP2015501783A5 (hr) | ||
| EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
| WO2011097372A3 (en) | Pterostilbene cocrystals | |
| MY165149A (en) | Use of binders for manufacturing storage stable formulations | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2013520405A5 (hr) | ||
| AU2011286276A8 (en) | Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases | |
| UA111415C2 (uk) | Фармацевтичний препарат, що містить похідну дигідрохіназоліну з противірусною активністю | |
| IN2013MU02206A (hr) | ||
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| WO2013057251A3 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| RU2014129508A (ru) | Новая комбинация | |
| WO2010121675A3 (en) | Thiazolyl-benzimidazoles | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| FR2961695B1 (fr) | Utilisation de composes dans le traitement ou la prevention de troubles cutanes | |
| WO2012163088A3 (zh) | 肾病和心脏病的治疗药物及其用途 |